TransMedics Q1 2026: Strong Start, Innovative Growth

TransMedics first quarter 2026 earnings show a strong start, with total revenue of $174 million, a 21% increase from last year and 8% from last quarter. U.S. transplant products grew by 22% year-over-year, while international sales jumped by 39% to $6 million. The company is focusing on growth, upgrading devices to their Gen3.0 platform and launching CHOPS, a controlled hypothermic preservation system. Investors are buzzing positive about the companys strategy, with Europe expansion and a deal with PAD Aviation for dedicated flights. Financials show gross margins at 58%, down from supply chain builds, but expected to normalize at 60% long-term. Guidance sticks firm for full-year revenue of $727-$757 million, representing 20-25% growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/104781e7999b6d9e